We can't find the internet
Attempting to reconnect
13071.1 PFLS-LS
13071.1 PFLS-LS
Résumé
Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients
Textes supplémentaires
Abstract
This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.
Participants
Christoph Kündig
Wirtschaftspartner
christoph.kundig@med-discovery.com
Med Discovery SA Christoph Kündig Route de la Corniche 4 1066 Epalinges VD CH
Thierry Buclin
Kontaktperson
thierry.buclin@chuv.ch
CHUV Centre Hospitalier Universitaire Va Thierry Buclin Rue du Bugnon 17 1011 Lausanne VD CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2013-02-28
- Date de fin
- 2016-09-30
- Coûts totaux approuvés
- CHF 482878.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%